NovoCure (NASDAQ: NVCR) shares soared 6.16% in pre-market trading on Thursday following the release of its third-quarter 2025 financial results, which surpassed analyst expectations. The oncology company, known for its innovative Tumor Treating Fields (TTFields) therapy, reported significant revenue growth and regulatory achievements, boosting investor confidence.
NovoCure's Q3 revenue reached $167.204 million, beating the analyst consensus estimate of $158.6 million by 5.03%. This represents an 8% increase compared to the same period last year, primarily driven by active patient growth and favorable exchange rates. The company's earnings per share (EPS) showed a loss of $(0.33), which was better than the expected loss of $(0.42), demonstrating improved financial performance despite ongoing investments in research and development.
Adding to the positive sentiment, NovoCure announced several regulatory milestones. In September 2025, the Japanese Ministry of Health, Labour and Welfare approved Optune Lua for use in combination with PD-1/PD-L1 inhibitors in adult patients with unresectable advanced or recurrent non-small cell lung cancer (NSCLC). Furthermore, the company's premarket approval application for TTFields therapy in pancreatic cancer is currently under substantive review by the U.S. Food and Drug Administration, potentially opening up new market opportunities. These developments, coupled with the strong financial results, appear to be driving the stock's pre-market rally as investors anticipate continued growth and expansion of NovoCure's innovative cancer treatments.
Comments